VERA VERA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, VERA THERAPEUTICS INC reported revenue of n/a, net income of −$109M and diluted EPS of −$1.52; for the fiscal year ended December 2025 revenue was n/a.
VERA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$315M, net income −$300M (margin n/a), EPS −$4.66
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$167M, net income −$152M (margin n/a), EPS −$2.75
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$102M, net income −$96.0M (margin n/a), EPS −$2.25
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$90.9M, net income −$89.1M (margin n/a), EPS −$3.35
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$34.4M, net income −$32.6M (margin n/a), EPS −$2.43
VERA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$109M, EPS −$1.52
- Quarter ended Mar 31, 2026: revenue n/a, net income −$121M, EPS −$1.69
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$91.1M, EPS −$1.39
- Quarter ended Sep 30, 2025: revenue n/a, net income −$80.3M, EPS −$1.26
- Quarter ended Jun 30, 2025: revenue n/a, net income −$76.5M, EPS −$1.20
- Quarter ended Mar 31, 2025: revenue n/a, net income −$51.7M, EPS −$0.81
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$43.4M, EPS −$0.72
- Quarter ended Sep 30, 2024: revenue n/a, net income −$46.6M, EPS −$0.85
- Quarter ended Jun 30, 2024: revenue n/a, net income −$33.7M, EPS −$0.62
- Quarter ended Mar 31, 2024: revenue n/a, net income −$28.4M, EPS −$0.56
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$25.7M, EPS −$0.54
- Quarter ended Sep 30, 2023: revenue n/a, net income −$20.1M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$20.2M, EPS −$0.46
- Quarter ended Mar 31, 2023: revenue n/a, net income −$30.1M, EPS −$0.80
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$32.4M, EPS −$1.18
- Quarter ended Sep 30, 2022: revenue n/a, net income −$24.7M, EPS −$0.91
- Quarter ended Jun 30, 2022: revenue n/a, net income −$14.9M, EPS −$0.55
- Quarter ended Mar 31, 2022: revenue n/a, net income −$17.1M, EPS −$0.71
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.8M, EPS $10.49
- Quarter ended Sep 30, 2021: revenue n/a, net income −$7.61M, EPS −$0.36
VERA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$241M, share buybacks $0
- Fiscal year ended Dec 2024: operating cash flow −$135M, share buybacks $13.0K
- Fiscal year ended Dec 2023: operating cash flow −$92.2M, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow −$67.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$23.7M, share buybacks n/a
VERA balance sheet
- Jun 30, 2026: cash $48.9M, total assets $533M, total liabilities $125M, shareholders' equity $408M
- Mar 31, 2026: cash $114M, total assets $622M, total liabilities $122M, shareholders' equity $500M
- Dec 31, 2025: cash $355M, total assets $735M, total liabilities $130M, shareholders' equity $605M
- Sep 30, 2025: cash $57.8M, total assets $518M, total liabilities $119M, shareholders' equity $399M
- Jun 30, 2025: cash $49.1M, total assets $579M, total liabilities $110M, shareholders' equity $468M
- Mar 31, 2025: cash $55.1M, total assets $610M, total liabilities $75.2M, shareholders' equity $535M
- Dec 31, 2024: cash $92.6M, total assets $656M, total liabilities $78.5M, shareholders' equity $577M
- Sep 30, 2024: cash $27.3M, total assets $369M, total liabilities $79.5M, shareholders' equity $289M
Is VERA profitable?
No. VERA THERAPEUTICS INC lost $402M over the last four quarters.
What is VERA's EPS?
Diluted earnings per share over the last four quarters were −$5.86; −$1.52 in the latest quarter.